12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Misoprostol vaginal insert regulatory update

FDA accepted for review an NDA from Ferring for misoprostol vaginal insert (MVI) to decrease the time to vaginal delivery in women undergoing labor with an unfavorable cervix when used...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >